Abstract
The Wnt/β-catenin signaling pathway is critical for normal mammalian development, the specification of epidermal cells and neoplastic transformation of intestinal epithelium. However, precise molecular information regarding cell-specific responses to β-catenin signaling has been limited. This question was addressed using a mouse model in which exon 3 of the β-catenin gene was deleted in several cell types with loxP-mediated recombination utilizing a Cre transgene under control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). The stabilization of β-catenin in prostate epithelium resulted in hyperplasias and extensive transdifferentiation into epidermal-like structures, which expressed keratins 1 and 6, filaggrin, loricrin and involucrin. The cell-specific loss of NKCC1 protein and reduced nuclear Stat5a is further suggestive of a loss of prostate epithelial characteristics. In addition to the prostate, hyperplasias and squamous metaplasias were detected in epithelia of the epididymis, vas deferens, coagulating gland, preputial gland and salivary gland. However, and in contrast to a recent study, no lesions reminiscent of high-grade prostate intraepithelial neoplasia were detected. Since β-catenin was activated in several cell types and impinged upon the viability of these mice, it was not possible to evaluate the cumulative effect over more than 3 months. To assess long-term consequences of β-catenin activation, mutant and control prostate tissues were transplanted into the mammary fat pads of wild-type males. Notably, squamous metaplasias, intra-acinous hyperplasia and possible neoplastic transformation were observed after a total of 18 weeks of β-catenin stimulation. This suggests that the transdifferentiation into squamous metaplasias is an early response of endoderm-derived cells to β-catenin, and that the development of intra-acinous hyperplasias or neoplastic foci is a later event.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- EST:
-
expressed sequence tag
- LTR:
-
long terminal repeat
- MMP:
-
matrix metalloproteinase
- MMTV:
-
mouse mammary tumor virus
- Stat:
-
signal transducer and activator of transcription
References
Achtstatter T, Moll R, Moore B and Franke WW . (1985). J. Histochem. Cytochem., 33, 415–426.
Alberts AS and Treisman R . (1998). EMBO J., 17, 4075–4085.
Barresi G and Tuccari G . (1984). Virchows Arch. A., 403, 59–66.
Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O and Hurta RA . (2001). Cell Biol. Int., 25, 411–420.
Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, McMahon AP, Sommer L, Boussadia O and Kemler R . (2001). Development, 128, 1253–1264.
Chesire DR, Ewing CM, Gage WR and Isaacs WB . (2002). Oncogene, 21, 2679–2694.
Chesire DR, Ewing CM, Sauvageot J, Bova GS and Isaacs WB . (2000). Prostate, 45, 323–334.
de Lau W and Clevers H . (2001). Nat. Genet., 28, 3–4.
DeOme KB, Faulkin Jr LJ, Bern HA and Blair PE . (1959). Cancer Res., 19, 515–520.
Fischer DF, van Drunen CM, Winkler GS, van de Putte P and Backendorf C . (1998). Nucleic Acids Res., 26, 5288–5294.
Fuchs E and Byrne C . (1994). Curr. Opin. Genet. Dev., 4, 725–736.
Gat U, DasGupta R, Degenstein L and Fuchs E . (1998). Cell, 95, 605–614.
Gerstein AV, Almeida TA, Zhao G, Chess E, Shih Ie M, Buhler K, Pienta K, Rubin MA, Vessella R and Papadopoulos N . (2002). Genes Chromosomes Cancer, 34, 9–16.
Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H and Khazaie K . (2002). Oncogene, 21, 4099–4107.
Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K and Kemler R . (1995). Development, 121, 3529–3537.
Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, Oshima M and Taketo MM . (2002). Cancer Res., 62, 1971–1977.
Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M and Taketo MM . (1999). EMBO J., 18, 5931–5942.
Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF and Waterman ML . (2001). Nat. Genet., 28, 53–57.
Huelsken J and Birchmeier W . (2001). Curr. Opin. Genet. Dev., 11, 547–553.
Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C and Birchmeier W . (2000). J. Cell Biol., 148, 567–578.
Huelsken J, Vogel R, Erdmann B, Cotsarelis G and Birchmeier W . (2001). Cell, 105, 533–545.
Humphreys RC and Hennighausen L . (1999). Cell Growth Differ., 10, 685–694.
Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS . (2001). Clin. Cancer Res., 7, 3113–3119.
Kondo M, Scherer DC, Miyamoto T, King AG, Akashi K, Sugamura K and Weissman IL (2000). Nature, 407, 383–386.
Krempler A, Henry MD, Triplet AA and Wagner KU . (2002). J. Biol. Chem., 277, 43216–43223.
Li XF, Thinakaran G, Sisodia SS and Yu FS . (1999). J. Biol. Chem., 274, 27249–27256.
Liu X, Robinson GW and Hennighausen L . (1996). Mol. Endocrinol., 10, 1496–1506.
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A and Hennighausen L . (1997). Genes Dev., 11, 179–186.
McCrea PD, Turck CW and Gumbiner B . (1991). Science, 254, 1359–1361.
Merrill BJ, Gat U, DasGupta R and Fuchs E . (2001). Genes Dev., 15, 1688–1705.
Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW and Hennighausen, L . (2001). J. Cell Biol., 155, 531–542.
Miyoshi K, Meyer B, Gruss P, Cui Y, Renou JP, Morgan FV, Smith GH, Reichenstein M, Shani, M and Hennighausen, L and Robinson, GW . (2002b). Mol. Endocrinol., 16, 2892–2901.
Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E, Xu X, Seldin DC, Schmidt EV, Taketo MM, Robinson GW, Cardiff RD and Hennighausen L . (2000c). Oncogene, 21, 5548–5556.
Miyoshi K, Shillingford JM, Le Provost F, Gounari F, Bronson R, von Boehmer H, Taketo MM, Cardiff RD, Hennighausen L and Khazaie K . (2002a). Proc. Natl. Acad. Sci. USA, 99, 219–224.
Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L and Rui H . (2000). Lab. Invest., 80, 993–1006.
Niemann C, Owens DM, Hulsken J, Birchmeier W and Watt PM . (2002). Development, 129, 95–109.
Oettgen P, Kas K, Dube A, Gu X, Grall F, Thamrongsak U, Akbarali Y, Finger E, Boltax J, Endress G, Munger K, Kunsch C and Libermann TA . (1999). J. Biol. Client., 274, 29439–29452.
Polakis P . (2000). Genes Dev., 14, 1837–1851.
Reese JH, McNeal JE, Goldenberg SL, Redwine EA and Sellers RG . (1992). Prostate, 20, 73–85.
Robinson GW, McKnight RA, Smith GH, Hennighausen L . (1995). Development, 121, 2079–2090.
Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J and Iruela-Arispe ML . (2001). Proc. Natl. Acad. Sci. USA, 98, 12485–12490.
Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T and Clevers H . (1999). Science, 285, 1923–1926.
Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL and MacDougald OA (2000). Science, 289, 950–953.
Shen X, Li J, Hu PP, Waddell D, Zhang J and Wang XF . (2001). J. Biol. Chem., 276, 15362–15368.
Shillingford JM, Miyoshi K, Flagella M, Shull GE and, Hennighausen L . (2002a). Mol. Endocrinol., 16, 1309–1321.
Shillingford JM, Miyoshi K, Robinson GW, Grimm SL, Rosen JM, Neubauer H, Pfeffer K and Hennighausen L . (2002b). Mol. Endocrinol., 16, 563–570.
Slunt HH, Thinakaran G, Von Koch C, Lo AC, Tanzi RE and Sisodia, SS .(1994). J. Biol. Chem., 269, 2637–2644.
Song HJ, Poy G, Darwiche N, Lichti U, Kuroki T, Steinert PM and Kartasova T (1999). Genomics, 55, 28–42.
Voeller HJ, Truica CI and Gelmann EP . (1998). Cancer Res., 58, 2520–2523.
Wagner KU, McAllister K, Ward T, Davis B, Wiseman R and Hennighausen L (2001). Transgenic Res., 10, 545–553.
Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA and Hennighausen L . (1997). Nucleic Acids Res., 25, 4323–4330.
Watt FM and Hogan BL . (2000). Science, 287, 1427–1430.
Widelitz RB, Jiang TX, Lu J and Chuong CM . (2000). Dev. Biol., 219, 98–114.
Acknowledgements
We acknowledge N Harada, who originally generated the floxed mice. Part of this work was supported by grants from the Ministry of Education, Science, Sports and Culture, Japan; and Organization for Pharmaceutical Safety and Research, Japan. The rabbit polyclonal NKCC1 antibody that has been previously described (Moore-Hoon and Turner, 1998), was a kind gift from Dr Jim Turner, National Institute of Craniofacial and Dental Research, NIH (Bethesda, MD, USA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bierie, B., Nozawa, M., Renou, JP. et al. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22, 3875–3887 (2003). https://doi.org/10.1038/sj.onc.1206426
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206426
Keywords
This article is cited by
-
Hyperphosphorylated PTEN exerts oncogenic properties
Nature Communications (2023)
-
Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
Stem Cell Research & Therapy (2022)
-
Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis
Oncogene (2020)
-
Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells
Oncogene (2019)
-
Low-level laser treatment stimulates hair growth via upregulating Wnt10b and β-catenin expression in C3H/HeJ mice
Lasers in Medical Science (2017)